DMC Biotechnologies unveils fermented D-chiro-inositol for hormonal and metabolic health

DMC Biotechnologies unveils its latest fermentation-derived ingredient, D-chiro-inositol, which is now commercially available in the US and a select few other markets. The company says this is a significant step forward in its expansion of sustainably produced health actives for supplement brands targeting metabolic and hormonal health.

The new D-chiro-inositol is produced through its proprietary precision fermentation platform and offers supplement manufacturers a cleaner, solvent-free alternative to conventional sources, while addressing increasing consumer demand for traceable and environmentally responsible sourcing. 

According to DMC Biotechnologies, the method delivers improved purity and a lower environmental footprint compared to traditional chemical synthesis.

“We’re proud to introduce fermented D-chiro-inositol as a next-generation ingredient for brands committed to clean and sustainable products,” says Rusty Pittman, the company’s VP of business development. “In addition, consumers increasingly care how products are made — with fermentation emerging as a preferred alternative to chemical processing.”

Focus on women’s and metabolic health

DMC Biotechnologies spotlights D-chiro-inositol as an isomer of inositol commonly found in dietary supplements that support insulin sensitivity, ovarian function, and hormonal balance. Commonly used in products addressing conditions such as polycystic ovary syndrome, it is also gaining traction in men’s health. A recent clinical study cited by DMC showed that D-chiro-inositol supplementation increased serum testosterone levels in men by 23%.

The ingredient complements the company’s earlier launch of myo-inositol, a more widely used inositol form. While each inositol isomer has distinct biological roles, the company says research suggests they may be more effective when formulated together. This gives brands the option to create more comprehensive inositol-based formulations from a single, sustainable supplier.

DMC Biotechnologies adds that its precision fermentation platform allows for consistent, scalable production of high-value bioactives while reducing reliance on petrochemicals and resource-intensive chemical processes. The company positions its fermentation technology as a key enabler for decarbonizing global supply chains in health and wellness.

“The launch of D-chiro-inositol builds on the momentum of our recent introduction of myo-inositol,” DMC Biotechnologies’ CEO, Jim Flatt, underscores. “Together, these products demonstrate DMC’s ability to quickly develop and commercialize important and sustainable human nutritional ingredients.”

“We’re continuing to expand our pipeline of nutraceutical and cosmetic actives — bringing the same quality, transparency, and environmental responsibility to every product we introduce.”